ANI Pharmaceuticals posts record Q2 2026 results above expectations, revenue $266M, adjusted EPS $2.21, issues 2026 guidance
- Full-year 2026 guidance set at $9.19–$9.69 EPS on $1.08–$1.14 billion in revenue.
- Company updates Cortrophin Gel revenue guidance to a $520–$540M range.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.